Aaron Cowen’s Tourmaline Bio TRML Stock Holding History

Aaron Cowen’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-125,000	Closed	-$1.61M	–	112
2024 Q2	$1.61M	Hold	125,000	–	–	0.06%	69
2024 Q1	$2.86M	Buy	+125,000	New	+$4.41M	0.11%	71

Other funds holding TRML

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Aaron Cowen's TRML Position: Q3 2024 in Review

Aaron Cowen sold out of Tourmaline Bio (TRML) in Q3 2024, closing a stake of 125,000 shares — an estimated $1.61M sold.

Aaron Cowen first reported a position in TRML in Q1 2024 and held it in 2 quarters. The position peaked at $2.86M in Q1 2024. 92 funds tracked by Wall St. Rank hold TRML as of Q3 2024.

Aaron Cowen reported no remaining Tourmaline Bio position as of Q3 2024 after selling out during the quarter.
Aaron Cowen sold 125,000 Tourmaline Bio shares in Q3 2024, an estimated $1.61M.
Aaron Cowen first reported a position in Tourmaline Bio in Q1 2024 and held it in 2 quarters.
Aaron Cowen's Tourmaline Bio position peaked at $2.86M in Q1 2024.
92 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2024.

Based on Suvretta Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.